European Mediscience Awards
Thursday 12 June 2025, Hotel InterContinental, London W1
Nominations open w/c Monday 3 March 2025
About
About the Awards
Showcasing achievement and success in the UK and European healthcare, biotech, pharmaceutical and life sciences sectors
The European Mediscience Awards is now in its 23rd year, having been held every year since inception in 2002*. The event is the largest annual gathering of private and publicly quoted healthcare, biotech and life sciences companies in Europe. Bringing together the best of European mediscience companies to celebrate achievement and recognise success, it is the must-attend event for anybody working in this sector.
Each year sees the attendance of over 500 quoted and private UK and European life sciences companies and their corporate advisers, analysts, fund managers, commentators and peers. The event is sold out from one year to the next.
The European Mediscience Awards 2025 will take place on Thursday 12 June at the Hotel InterContinental, London, W1.
*with the exception of 2020 when we were unable to hold a live event due to COVID-19, but instead held a successful digital campaign.
TESTIMONIALS FROM THE 2024 AWARDS
James Paton-Philip, Partner, Hill Dickinson LLP:
“Just a short note to thank you again for a lovely evening at the Awards. It was another extremely well organised and enjoyable event.”
Holly Molyneux, Head of Business Development, Stephenson Harwood LLP:
“I just wanted to say thank you for all your help. I have heard great feedback from our team about the event. They said it is the best life sciences awards that we attend in terms of organisation, format, food etc.”
Joanne Beartup, Global Head, Conference & Event Marketing, RBC Capital Markets:
“It was lovely working with you both again and looking forward to continuing the partnership next year!”
James Steel, Head of Healthcare & Life Sciences, Peel Hunt:
“Many thanks indeed for inviting me to a really enjoyable Mediscience event and great to see so many familiar faces. I really enjoyed speaking to Tanni Grey-Thompson, a really down to earth lady with an amazing CV post a remarkable Paralympics career – all rather humbling!”
Max Herrmann, Managing Director, Stifel Financial Corporation:
“It was great to see you all yesterday evening at the Mediscience Awards. It truly was a fun and memorable event.”
Vadim Alexandre, Head of Healthcare, SP Angel:
“It was another stellar awards night. Everything was very well organised. Well done! Many thanks to you and the team for hosting such a well-run event.”
Sponsors
ICR Consilium is a global leader in financial and corporate communications and investor relations focused on the healthcare sector. Based in Europe with offices across the US, we provide strategic, long-term advice to privately held and listed international healthcare companies and their Boards, senior decision-makers and executives.
Our clients trust us to translate complex healthcare situations into clear messaging and meaningful communications programmes that deliver sustained results, inspire action and build shareholder value. We have established deep knowledge and expertise across all areas of healthcare, and are proud of our team, our network and our partnership with our clients. ICR Consilium is part of the ICR Global Group.
For more information, please see
Mainline sponsor:
ICR Consilium is a global leader in financial and corporate communications and investor relations focused on the healthcare sector. Based in Europe with offices across the US, we provide strategic, long-term advice to privately held and listed international healthcare companies and their Boards, senior decision-makers and executives.
Our clients trust us to translate complex healthcare situations into clear messaging and meaningful communications programmes that deliver sustained results, inspire action and build shareholder value. We have established deep knowledge and expertise across all areas of healthcare, and are proud of our team, our network and our partnership with our clients. ICR Consilium is part of the ICR Global Group.
For more information, please see
FTI Consulting has built an unrivalled, global strategic communications offering to life science and healthcare companies. Our large team of life sciences and healthcare specialists has the breadth and depth of experience, in pharmaceuticals, biotech, medical devices, digital health and healthcare services, to help you ensure that the right message reaches the right audience at the right time.
We take a holistic view, helping clients, ranging from top-10 global pharmaceutical and medical device companies to small start-ups, to develop and defend their reputations; seek to attract and retain the best talent; navigate and inform health and policy agendas; and steady themselves for moments of change or periods of growth.
Whether you need support for capital markets transactions or fundraisings, digital and social media strategies to meet growing sector demand; internal change communication after transactions; market preparedness and product launch communications; crisis preparedness or response, clinical and regulatory milestone communications; corporate messaging or public affairs support, FTI has the expertise and capabilities to help you.
www.fticonsulting-emea.com/industries/healthcare-and-life-sciences
FTI Consulting has built an unrivalled, global strategic communications offering to life science and healthcare companies. Our large team of life sciences and healthcare specialists has the breadth and depth of experience, in pharmaceuticals, biotech, medical devices, digital health and healthcare services, to help you ensure that the right message reaches the right audience at the right time.
We take a holistic view, helping clients, ranging from top-10 global pharmaceutical and medical device companies to small start-ups, to develop and defend their reputations; seek to attract and retain the best talent; navigate and inform health and policy agendas; and steady themselves for moments of change or periods of growth.
Whether you need support for capital markets transactions or fundraisings, digital and social media strategies to meet growing sector demand; internal change communication after transactions; market preparedness and product launch communications; crisis preparedness or response, clinical and regulatory milestone communications; corporate messaging or public affairs support, FTI has the expertise and capabilities to help you.
www.fticonsulting-emea.com/industries/healthcare-and-life-sciences
RBC Capital Markets is the Global Investment Banking, Advisory and Capital Markets division of Royal Bank of Canada (RBC). RBC is a leading, diversified provider of financial services and one of the strongest banks globally, the 9th largest bank globally and the 5th largest in North America, as measured by market capitalization. RBC is also one of the best rated with a credit rating of Aa1 (Moody’s) and AA- (S&P).
Recognized as a trusted and innovative partner for clients around the globe. RBC Capital Markets has been in the UK for over 100 years, with 60 offices worldwide. We are present in 16 countries, 7 of which are in Europe including London as our European Headquarters.
RBC Capital Markets Investment Banking division provides advisory and execution services to Corporate, Sponsor and institutional clients across ECM and Corporate Broking, DCM, Leverage Finance and M&A.
Its Equities division provides All Cap sales, research and trading services to institutional clients globally. Embedded within the broader team is a UK focused group of sales, research and trading professionals dedicated to both Mid Cap and Growth UK listed businesses.
RBC Capital Markets is the Global Investment Banking, Advisory and Capital Markets division of Royal Bank of Canada (RBC). RBC is a leading, diversified provider of financial services and one of the strongest banks globally, the 9th largest bank globally and the 5th largest in North America, as measured by market capitalization. RBC is also one of the best rated with a credit rating of Aa1 (Moody’s) and AA- (S&P).
Recognized as a trusted and innovative partner for clients around the globe. RBC Capital Markets has been in the UK for over 100 years, with 60 offices worldwide. We are present in 16 countries, 7 of which are in Europe including London as our European Headquarters.
RBC Capital Markets Investment Banking division provides advisory and execution services to Corporate, Sponsor and institutional clients across ECM and Corporate Broking, DCM, Leverage Finance and M&A.
Its Equities division provides All Cap sales, research and trading services to institutional clients globally. Embedded within the broader team is a UK focused group of sales, research and trading professionals dedicated to both Mid Cap and Growth UK listed businesses.
HSBC Innovation Banking provides commercial banking services, expertise and insights to the technology, life science and healthcare, private equity and venture capital industries.
HSBC Innovation Banking UK is a subsidiary of HSBC Group, benefiting from its stability, strong credit rating and international reach to help fuel its growth.
HSBC Innovation Banking provides commercial banking services, expertise and insights to the technology, life science and healthcare, private equity and venture capital industries.
HSBC Innovation Banking UK is a subsidiary of HSBC Group, benefiting from its stability, strong credit rating and international reach to help fuel its growth.
MEDiSTRAVA is a next-generation life sciences strategic communications and medical advisory firm working with biopharma and medtech companies at all stages of development, from start-up to beyond commercialisation.
We provide real-world insight and expertise that helps clients create the foundations for and deliver successful fund raisings, partnerships and development strategies designed to increase the chances of regulatory approval and optimise access to and the adoption of innovative products for patients in need.
Our multifunctional teams support our partners with scalable and targeted solutions across strategic corporate, investor, scientific and clinical communications, market access, medical and regulatory affairs, clinical trial optimisation, patient engagement, HEOR and real-world evidence, and advanced medical analytics.
We help our clients navigate each pivotal milestone in their journey with the ultimate goal being to ensure that more patients get the new treatments they need faster, delivering value to all stakeholders.
MEDiSTRAVA is a next-generation life sciences strategic communications and medical advisory firm working with biopharma and medtech companies at all stages of development, from start-up to beyond commercialisation.
We provide real-world insight and expertise that helps clients create the foundations for and deliver successful fund raisings, partnerships and development strategies designed to increase the chances of regulatory approval and optimise access to and the adoption of innovative products for patients in need.
Our multifunctional teams support our partners with scalable and targeted solutions across strategic corporate, investor, scientific and clinical communications, market access, medical and regulatory affairs, clinical trial optimisation, patient engagement, HEOR and real-world evidence, and advanced medical analytics.
We help our clients navigate each pivotal milestone in their journey with the ultimate goal being to ensure that more patients get the new treatments they need faster, delivering value to all stakeholders.
Edison is a content-led IR business operating in all major capital markets. With its unique approach integrating analyst content, digital targeting and investor engagement, Edison has a proven history of increasing liquidity and valuations for its clients. By building bigger, better informed and more engaged audiences, Edison ensures its clients standout in the marketplace. Edison’s content is viewable by any investor, anywhere in the world.
Edison is authorised and regulated by the Financial Conduct Authority (FCA)
Edison is a content-led IR business operating in all major capital markets. With its unique approach integrating analyst content, digital targeting and investor engagement, Edison has a proven history of increasing liquidity and valuations for its clients. By building bigger, better informed and more engaged audiences, Edison ensures its clients standout in the marketplace. Edison’s content is viewable by any investor, anywhere in the world.
Edison is authorised and regulated by the Financial Conduct Authority (FCA)
SP Angel provides broking and corporate finance advisory services to over 60 companies across the Healthcare, Technology and Natural Resources sectors. Our Healthcare Team has a proven track record in raising funds for both private and quoted companies.
SP Angel provides broking and corporate finance advisory services to over 60 companies across the Healthcare, Technology and Natural Resources sectors. Our Healthcare Team has a proven track record in raising funds for both private and quoted companies.
Panmure Gordon, an innovative and forward-thinking investment bank, helps fast-growing corporate and institutional clients achieve their ambitions and has offices in London, Leeds and New York. It provides a full range of services including Corporate Broking, Corporate Advisory, Capital Raising, Investor Relations, Research, Sales, Sales Trading and Market Making.
Panmure Gordon, an innovative and forward-thinking investment bank, helps fast-growing corporate and institutional clients achieve their ambitions and has offices in London, Leeds and New York. It provides a full range of services including Corporate Broking, Corporate Advisory, Capital Raising, Investor Relations, Research, Sales, Sales Trading and Market Making.
Cavendish is a champion for ambitious growth and investment companies. The Group is trusted by public and private companies, operating across industry sectors, to deliver expert services in equity capital markets, M&A, debt advisory and growth capital.
Cavendish has offices in London and Edinburgh and has a global reach through its membership of Oaklins.
Cavendish is a champion for ambitious growth and investment companies. The Group is trusted by public and private companies, operating across industry sectors, to deliver expert services in equity capital markets, M&A, debt advisory and growth capital.
Cavendish has offices in London and Edinburgh and has a global reach through its membership of Oaklins.
Awards
covering the period 1 April 2024 to 31 March 2025
Nominations open w/c Monday 3 March 2025
Key dates
Click on each award to view more information
BEST COMMUNICATION AWARD
Sponsored by:
BEST COMMUNICATION AWARD
Sponsored by
Criteria
Successful communication is vital to the development of mediscience companies.
Newsflow, both good and bad, can have a significant effect on share prices, and the winner of this award will have demonstrated its ability to successfully communicate its investment message to its target audience.
2024 Winner
MoonLake Immunotherapeutics AG
2024 Shortlist
- Hikma Pharmaceuticals plc
- hVIVO plc
- MoonLake Immunotherapeutics AG
- Syncona Ltd
- Tissue Regenix Group plc
- Verona Pharma plc
BREAKTHROUGH OF THE YEAR AWARD
Sponsored by:
BREAKTHROUGH OF THE YEAR AWARD
Sponsored by
Criteria
The winner of this award will be the company or organisation which has achieved the most significant breakthrough during the period 1 April 2024 to 31 March 2025.
This breakthrough could be a new discovery, departure or breakthrough in technology, a significant positive change in its financial position, or other breakthrough which has added significantly to the company’s or organisation’s fortunes.
2024 Winner
2024 Shortlist
- CRISPR Therapeutics AG
- Kooth plc
- Newron Pharmaceuticals SpA
- Santhera Pharmaceuticals
- Valneva SE
- Zealand Pharma A/S
BEST TECHNOLOGY AWARD
Sponsored by:
BEST TECHNOLOGY AWARD
Sponsored by
Criteria
The technology that lies at the heart of this award does not have to be proven, but it will, in the eyes of the Voting Panel, be innovative, well funded, and capable of significant commercial success. The technology concerned could have been developed within the organisation or acquired.
2024 Winner
2024 Shortlist
- 4basebio plc
- Avacta Group plc
- BiVictriX Therapeutics plc
- Creo Medical Group plc
- CRISPR Therapeutics AG
- MaxCyte, Inc.
THE EMERGING STAR AWARD
Sponsored by:
THE EMERGING STAR AWARD
Sponsored by
Criteria
The Emerging Star will be a private or young public mediscience company that has demonstrable credibility in terms of business model/strategy, management team and financing. The winner's focus on innovation will also be key, with its technology/IP capable of significant market impact or disruption.
The Emerging Star may not be able to demonstrate too much of a track record, but it will be judged against the demanding criteria that exist for its quoted company peers. The purpose of this award is to broaden knowledge, exchange ideas and help private businesses understand what could be required of them in the quoted company universe.
2024 Winner
2024 Shortlist
- AstronauTx Ltd
- Autifony Therapeutics Ltd
- CHARM Therapeutics Ltd
- NMD Pharma A/S
- Nuclera Ltd
- Quell Therapeutics Ltd
- Sitryx Therapeutics
- Tubulis Gmbh
MEDISCIENCE MEDIA COMMENTATOR OF THE YEAR AWARD
Sponsored by:
MEDISCIENCE MEDIA COMMENTATOR OF THE YEAR AWARD
Sponsored by
Criteria
This award recognises the importance of clear and concise commentary on the sector. It could be awarded to a journalist, a columnist, a specialist website or a team that is dedicated to providing sharp, perceptive and penetrating commentary about the sector.
In-depth knowledge of the sector is a given; the Voting Panel will be looking for excellence in the way that knowledge is communicated to the wider audience.
2024 Winner
2024 Shortlist
- Biotech Hangout
- Stephen Hansen/BioCentury
- Hannah Kuchler/Financial Times
- Natasha Loder/The Economist
- Brad Loncar/BiotechTV
- Melanie Senior
CAPITAL MARKET TRANSACTION OF THE YEAR AWARD
Sponsored by:
CAPITAL MARKET TRANSACTION OF THE YEAR AWARD
Sponsored by
Criteria
This award recognises a significant capital market transaction during our period under review. The capital market transaction could be an IPO or a follow-on financing; it would be significant in scope and transformational in nature and would materially enhance the prospects for the business in the short, medium and long term.
In deciding the shortlist and eventual winner, the Voting Panel will take into account the amount raised, stock price performance and the quality of the share register.
2024 Winner
2024 Shortlist
- argenx
- Autolus Therapeutics plc
- Bicycle Therapeutics plc
- Galderma Group AG
- Kooth plc
- SCHOTT Pharma
MOST SIGNIFICANT CONTRIBUTION TO THE MEDISCIENCE SECTOR AWARD
Sponsored by:
MOST SIGNIFICANT CONTRIBUTION TO THE MEDISCIENCE SECTOR AWARD
Sponsored by
Criteria
The winner of this award could be an individual, a company, a government department, research council, etc. who has made the single, biggest, most significant contribution to the sector. Difficult to define, but the Voting Panel will be aware of, and make allowances for, this fact.
2024 Winner
2024 Shortlist
- Jennifer Doudna, Emmanuelle Charpentier & Francisco Mojica
- EBD Group
- LifeArc
- Ruth McKernan
- Novo Nordisk Foundation
CHIEF EXECUTIVE OF THE YEAR AWARD
Sponsored by:
CHIEF EXECUTIVE OF THE YEAR AWARD
Sponsored by
Criteria
The winner will be an individual who has demonstrated exceptional leadership qualities during the year under review. The creation of shareholder value through drive, vision and flair in taking his or her business forward are the qualities the Voting Panel is looking for. The winner will also have recognised the importance of developing a management team and workforce in supporting corporate success.
2024 Winner
2024 Shortlist
- Karim Bitar/Convatec plc
- Christian Itin/Autolus Therapeutics plc
- Yamin ‘Mo’ Khan/hVIVO plc
- Daniel Lee/Tissue Regenix Group plc
- Flemming Ørnskov/Galderma Group AG
- Jorge Santos da Silva/MoonLake Immunotherapeutics AG
- Adam Steensberg/Zealand Pharma A/S
- Fredrik Tiberg/Camurus AB
COMPANY OF THE YEAR AWARD
Sponsored by:
COMPANY OF THE YEAR AWARD
Sponsored by
Criteria
The Company of the Year will already have gained recognition by analysts and investors.
It will be a well managed, soundly financed growth business with a well defined strategy to deliver its key financial, ethical and social ambitions. Put simply, the Voting Panel are not necessarily looking for the biggest, but they are looking for the best.
2024 Winner
2024 Shortlist
- Camurus AB
- CRISPR Therapeutics AG
- MoonLake Immunotherapeutics AG
- PureTech Health plc
- Recordati SpA
- Zealand Pharma A/S
Voting panel
The Voting Panel will meet to discuss this year's nominations on Thursday 1 May 2025. Members of the full 2025 Voting Panel will be announced on this page in due course.
Click below to see judges from past events.
The 2024 Voting Panel
The event
Sponsorship
Sponsorship opportunities sometimes become available, including sponsorship of an individual award, sponsorship of the official drinks reception or sponsorship of the menu. Sponsorship opportunities are, by their very nature, limited. Costs and availability on request.
Hosting a table
Reservations are available for tables of ten people. Numbers are strictly limited and reservations are taken on a first come, first served basis.
Advertising
Advertising in the digital brochure is welcomed and enables your key messages to reach a highly targeted audience. The digital event brochure is available to download on the night and contains details of the all nominees, the programme for the night and the menu. Uniquely, it also contains the names of all attendees, in alphabetical and table order. Thus it is widely used as a reference post event for up to a year afterwards.
Bespoke sponsorship opportunities
We offer a range of bespoke sponsorship packages, tailor made to suit your marketing objectives and budget. Further information on request.
Enquiries
For all enquiries relating to the European Mediscience Awards, please do get in touch with jo.thomas@ford-sinclair.co.uk.
Key details for guests
Date
Thursday 12 June 2025
Venue
Ballroom, Hotel InterContinental
One Hamilton Place
Park Lane
London W1J 7QY
Start time
6.00 p.m. – Drinks reception
7.30 p.m. – Dinner
9.15 p.m. – Awards
9.45 p.m. – After-dinner entertainment
12.00 midnight – Carriages
Dress code
Black Tie
Charity collection
A charity collection will be taken up during the course of the evening and the European Mediscience Awards team will be available throughout to accept contactless donations. Thank you in advance for your generosity.
Accommodation
Hotel InterContinental
Exclusive rates for bedrooms may be available for guests attending the event and further information will be available in due course.
Location
Latest media
Charity
2024 Charity Collection
A charity collection was held at the European Mediscience Awards 2024 in respect of two charities: BCCS and The Brain Tumour Society. The total amount raised which was split equally between these two charities was:
£8,270
BCCS provides highly professional and well‑supported Social Workers and Counsellors to help children and young people who are in need.
BCCS works in the East End of London and Essex with children, young people and their families and schools to help them overcome emotional difficulties, behavioural problems and their root causes. The prime focus of the work is to provide an early intervention service to enable them to address difficulties that may be impeding their educational, social and emotional development.
The Brain Tumour Charity is the UK’s largest dedicated brain tumour charity, committed to fighting brain tumours on all fronts. It invests in pioneering research, in the UK and internationally, to increase survival and improve treatment options, and raises awareness of the symptoms of brain tumours to bring about earlier diagnosis.
It also offers a comprehensive support and information service for anyone who is affected by a brain tumour diagnosis, including a support and information line, Information Standard accredited fact sheets, online peer-to-peer support and a dedicated Children and Families Service.